BiotechTube

Bacillus Clausii

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastroenteritis

Conditions

Gastroenteritis

Trial Timeline

Mar 1, 2007 → —

NCT ID
NCT00457353

About Bacillus Clausii

Bacillus Clausii is a phase 3 stage product being developed by Sanofi for Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00457353. Target conditions include Gastroenteritis.

What happened to similar drugs?

1 of 10 similar drugs in Gastroenteritis were approved

Approved (1) Terminated (1) Active (8)
✅Bacillus clausii + Oral Rehydration TherapySanofiApproved
🔄mRNA-1403ModernaPhase 3
❌Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
🔄Rotavirus Vaccine, Live, Oral, PentavalentMerckPhase 3
🔄RotaTeq (V260) + IPVMerckPhase 3
🔄V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
🔄Prulifloxacin + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00457353Phase 3Completed
NCT00424905ApprovedCompleted

Competing Products

20 competing products in Gastroenteritis

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
Placebo + HIL-214HilleVaxPhase 1
19
HIL-214 + PlaceboHilleVaxPhase 2/3
28
HIL-214HilleVaxPhase 2
25
HIL-214 + PlaceboHilleVaxPhase 2/3
20
Benralizumab + PlaceboAstraZenecaPhase 2/3
38
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)MerckPhase 3
32
Rotavirus VaccineMerckPre-clinical
18
Rotavirus Vaccine, Live, Oral, PentavalentMerckPhase 3
40
RotaTeq (V260) + IPVMerckPhase 3
40
V260 + Placebo to V260 + OPV + DTaPMerckPhase 3
40
Prulifloxacin + PlaceboMerckPhase 3
40
Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: PlaceboMerckPhase 1
29
RotaTeq™ experimental formulation + RotaTeq™ existing formulationMerckPhase 3
40
prulifloxacinMerckPhase 3
40
montelukastMerckPre-clinical
26
Bacillus clausii + Oral Rehydration TherapySanofiApproved
43
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19